Stuttgart - Delayed Quote EUR
Biomark Diagnostics Inc (20B.SG)
0.1640
+0.0080
+(5.13%)
At close: 9:47:54 PM GMT+2
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
155.0290
163.2200
153.4920
43.9330
0
Operating Expense
1,954.4880
1,479.9360
1,885.5680
1,447.0390
1,082.6450
Operating Income
-1,799.4590
-1,316.7160
-1,732.0760
-1,403.1060
-1,082.6450
Net Non Operating Interest Income Expense
-97.7200
-111.3070
-110.1530
-49.6830
-4.0780
Other Income Expense
0.5230
0.6380
--
-1.1140
-7.4670
Pretax Income
-1,896.6560
-1,427.3850
-1,842.2290
-1,453.9030
-1,094.1900
Net Income Common Stockholders
-1,896.6560
-1,427.3850
-1,842.2290
-1,453.9030
-1,094.1900
Diluted NI Available to Com Stockholders
-1,896.6560
-1,427.3850
-1,842.2290
-1,453.9030
-1,094.1900
Basic EPS
-0.02
-0.02
-0.02
-0.02
-0.02
Diluted EPS
-0.02
-0.02
-0.02
-0.02
-0.02
Basic Average Shares
85,238.1420
85,238.1420
82,777.8840
77,928.5850
73,304.9060
Diluted Average Shares
85,238.1420
85,238.1420
82,777.8840
77,928.5850
73,304.9060
Total Expenses
1,954.4880
1,479.9360
1,885.5680
1,447.0390
1,082.6450
Net Income from Continuing & Discontinued Operation
-1,896.6560
-1,427.3850
-1,842.2290
-1,453.9030
-1,094.1900
Normalized Income
-1,897.1790
-1,428.0230
-1,842.2290
-1,452.7890
-1,086.7230
Interest Income
0.4150
3.8610
0.0790
0
0.0600
Interest Expense
98.1350
115.1680
110.2320
49.6830
4.1380
Net Interest Income
-97.7200
-111.3070
-110.1530
-49.6830
-4.0780
EBIT
-1,798.5210
-1,312.2170
-1,731.9970
-1,404.2200
-1,090.0520
EBITDA
-1,523.2560
-919.0470
-1,345.8010
-1,224.5980
-1,076.3660
Reconciled Depreciation
275.2650
393.1700
386.1960
179.6220
13.6860
Net Income from Continuing Operation Net Minority Interest
-1,896.6560
-1,427.3850
-1,842.2290
-1,453.9030
-1,094.1900
Total Unusual Items Excluding Goodwill
0.5230
0.6380
0
-1.1140
-7.4670
Total Unusual Items
0.5230
0.6380
0
-1.1140
-7.4670
Normalized EBITDA
-1,523.7790
-919.6850
-1,345.8010
-1,223.4840
-1,068.8990
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
3/31/2021 - 8/28/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade